CardioDiagnostics Inc. (CDIO)

Executive Summary

CardioDiagnostics Inc. is a private, US-based biotechnology company leveraging artificial intelligence and epigenetic/genetic biomarkers to develop precision cardiovascular diagnostic tests. Founded in 2015 and headquartered in Chicago, the company focuses on assessing heart attack risk and managing coronary heart disease. Its AI-driven platform integrates multi-omic data to deliver actionable insights for patients, healthcare providers, and employers. Despite a modest valuation of approximately $5 million, CardioDiagnostics occupies a niche in the rapidly growing precision cardiology market, which is fueled by rising cardiovascular disease prevalence and demand for non-invasive, personalized diagnostics. The company's early-stage pipeline and lack of disclosed funding or commercial products suggest it is still in the development or validation phase, with potential to disrupt traditional risk stratification tools if clinical and regulatory milestones are achieved.

Upcoming Catalysts (preview)

• Q4 2026Pivotal clinical study results for AI-driven heart attack risk test45% success
• Q2 2027FDA submission for lead diagnostic product30% success
• Q3 2026Strategic partnership with major healthcare provider or diagnostic lab50% success